share_log

Senti Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer KNOBELMAN DEBORAH

SEC announcement ·  Feb 2 17:27
Summary by Moomoo AI
Deborah Knobelman, Chief Financial Officer and Head of Corporate Development at Senti Biosciences, Inc., completed a stock acquisition on February 1, 2024. The transaction involved a grant of 101,000 shares of common stock at no cost. Following the transaction, Knobelman's direct holdings in the company increased to a total of 131,000 shares. The grant is part of the company's compensation structure and reflects the ongoing commitment of the executive to the company's future.
Deborah Knobelman, Chief Financial Officer and Head of Corporate Development at Senti Biosciences, Inc., completed a stock acquisition on February 1, 2024. The transaction involved a grant of 101,000 shares of common stock at no cost. Following the transaction, Knobelman's direct holdings in the company increased to a total of 131,000 shares. The grant is part of the company's compensation structure and reflects the ongoing commitment of the executive to the company's future.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more